➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Boehringer Ingelheim
Johnson and Johnson
Merck
Express Scripts

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,686,034


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,686,034 protect, and when does it expire?

Patent 8,686,034 protects HORIZANT and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 8,686,034
Title:Crystalline form of .gamma.-aminobutyric acid analog
Abstract: A crystalline form of a .gamma.-aminobutyric acid analog, and methods of preparing same, are provided.
Inventor(s): Estrada; Tono (Santa Clara, CA), Raillard; Stephen P. (Mountain View, CA), Frauenfelder; Christine (Glis, CH), Zacher; Uwe (Brig, CH)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Application Number:13/164,620
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,686,034

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS ⤷  Free Forever Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ⤷  Free Forever Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ⤷  Free Forever Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,686,034

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 516801 ⤷  Free Forever Trial
Australia 2004282192 ⤷  Free Forever Trial
Brazil PI0415288 ⤷  Free Forever Trial
Canada 2541752 ⤷  Free Forever Trial
China 1867322 ⤷  Free Forever Trial
Cyprus 1113583 ⤷  Free Forever Trial
Denmark 1677767 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Express Scripts
Medtronic
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.